DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals" report to their offering.
Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR).
Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on this field of adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.
Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development.
What will you find in the report?
- Profiles of 34 companies active in the field
- Comprehensive description of 23 established and emerging T-cell or NK-cell redirecting antibodies
- Profiles of two approved and 45 T-cell or NK-cell redirecting bispecific antibodies in all phases of development
- Key characteristics of technologies with clinical stage drug candidates
- Emerging alternative bi- and trispecific formats
- Target selection and competition in drug candidates
- Competition of recombinant bispecific molecules with alternative treatment modalities
Companies Mentioned Include:
- Adimab
- Affimed Therapeutics
- Alligator Biosciences
- Ambrx
- Amgen
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- CytomX
- Eli Lilly
- Emergent BioSolutions
- EngMab
- Eureka Therapeutics
- GEMoaB
- Generon
- Genmab
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Pfizer
- Pieris Pharmaceuticals
- Regeneron Pharmaceuticals
- Roche
- Servier
- Wuhan YZY Biopharma
- Xencor
-
Zymeworks
Report Structure:
1. Introduction
2. Executive Summary
3. Competitive Landscape Analysis
4. Company Profiles
5. Technology Profiles
6. Drug & Drug Candidate Profiles
7. References
8. Attachment
For more information about this report visit http://www.researchandmarkets.com/research/ckb55n/tcell
